➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
McKinsey
Express Scripts
Johnson and Johnson
Boehringer Ingelheim

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for CCX168


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug CCX168?

CCX168 is an investigational drug.

There have been 7 clinical trials for CCX168. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2016.

The most common disease conditions in clinical trials are Vasculitis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, and Hemolytic-Uremic Syndrome. The leading clinical trial sponsors are ChemoCentryx, Mario Negri Institute for Pharmacological Research, and [disabled in preview].

There are nine US patents protecting this investigational drug and one hundred and one international patents.

Recent Clinical Trials for CCX168
TitleSponsorPhase
Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis SuppurativaChemoCentryxPhase 2
Controlled Trial Evaluating Avacopan in C3 GlomerulopathyChemoCentryxPhase 2
A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated VasculitisChemoCentryxPhase 3

See all CCX168 clinical trials

Clinical Trial Summary for CCX168

Top disease conditions for CCX168
Top clinical trial sponsors for CCX168

See all CCX168 clinical trials

US Patents for CCX168

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CCX168   Start Trial C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA)   Start Trial
CCX168   Start Trial Processes and intermediates in the preparation of C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA)   Start Trial
CCX168   Start Trial Soluble C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA)   Start Trial
CCX168   Start Trial Treatment of inflammatory diseases with inhibitors of C5a activity InflaRx GmbH (Jena, DE)   Start Trial
CCX168   Start Trial C5aR antagonists Chemocentryx, Inc. (Mountain View, CA)   Start Trial
CCX168   Start Trial C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CCX168

Drugname Country Document Number Estimated Expiration Related US Patent
CCX168 Argentina 077162 2028-12-22   Start Trial
CCX168 Australia 2009330194 2028-12-22   Start Trial
CCX168 Brazil 112012033075 2028-12-22   Start Trial
CCX168 Brazil PI0923384 2028-12-22   Start Trial
CCX168 Canada 2747522 2028-12-22   Start Trial
CCX168 Canada 2965223 2028-12-22   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Mallinckrodt
Harvard Business School
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.